Deutsche Bank AG
- WKN: 514000
- ISIN: DE0005140008
- Land: Deutschland
Nachricht vom 04.05.2021 | 09:16
Deutsche Bank to issue Additional Tier 1 capital instruments
Deutsche Bank AG / Key word(s): Issue of Debt
Frankfurt am Main, 4 May 2021 - Deutsche Bank AG (XETRA: DBKGn.DE / NYSE: DB) today announced its intention to issue securities that qualify as Additional Tier 1 capital instruments. The issuance is expected to be of benchmark size.
This transaction further strengthens Deutsche Bank's capital position, thereby contributing to the bank's deployment of capital in support of clients. The issuance partly offsets the impact of certain regulatory changes anticipated during the second quarter of 2021. It also supports achievement of Deutsche Bank's target of a leverage ratio of 4.5% on a fully loaded basis.
Issuance of these securities is covered by the authorization granted by the Annual General Meeting in 2018. The denominations of the securities will be EUR 200,000. Deutsche Bank AG will act as sole bookrunner for the placement.
The securities of Deutsche Bank AG mentioned in this release have not been registered under the Securities Act of 1933, as amended ("Securities Act") and will be issued under Regulation S of the Securities Act only and may not be offered, sold or delivered within the United States absent registration under the Securities Act or an exemption from registration requirements.
Deutsche Bank AG
Christian Streckert +49 69 910 38079
Eduard Stipic +49 69 910 41864
|Company:||Deutsche Bank AG|
|60325 Frankfurt a. M.|
|Phone:||+49 (0)69 910-00|
|Fax:||+49 (0)69 910-43800|
|Indices:||DAX, EURO STOXX 50|
|Listed:||Regulated Market in Berlin, Dusseldorf, Frankfurt (Prime Standard), Hamburg, Hanover, Munich, Stuttgart; Regulated Unofficial Market in Tradegate Exchange; NYSE|
|EQS News ID:||1192037|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
28. November 08:00 E-Mobilität Batterie Index: Unaufhaltsam
28. November 08:19 DAX-Wochenausblick: Omikron verdirbt die Jahresendrally – oder?
28. November 08:30 TSI USA: 100 Prozent Plus? Keine Besonderheit!
28. November 09:29 Mit System zu den Top-Performern wie Tesla oder Nvidia
28. November 10:00 Biotech-Kursexplosion voraus – dieser Hot-Stock bläst jetzt zum ...
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021